📰 Program Updates News
Page 10 - Program Updates News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Program Updates. Real-time updates on events, politics, business and more.
December 11, 2023
Completed enrollment of the LEAD Phase 1/2 clinical trial of LX1001 for the treatment of APOE4-associated Alzheimer’s disease
December 11, 2023
If olive oil is made from olives, what is baby oil made from? The regulatory framework, some would say “tangled web,” facing lenders is made from hundreds of federal, state, state, local, and quasi-governmental bodies. Analogies aside, near the top of the heap is the Consumer Finance Protection Bureau. The CFPB makes its priorities known and is concerned with redlining among other things. The CFPB can’t do anything about rising credit score costs, but for some reason people ...
December 3, 2023
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
November 30, 2023
The fastest-growing loyalty program in the hospitality industry enhances the travel journey with the industry’s first 150-night Milestone Reward and the reimagined Guest of Honor award ...
November 24, 2023
Exclusive TEMU promo code: Use code “aff07203” for up to 50% OFF. We’re here to discuss the TEMU Affiliate Program and how it can become your passive ...
November 7, 2023
Received 430 new patient start forms for FILSPARI® in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI...
November 6, 2023
Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on...
November 2, 2023
US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference...
October 17, 2023
New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B